These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33895011)

  • 61. Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
    Alfred Witjes J
    Eur Urol; 2021 Jul; 80(1):113. PubMed ID: 33593656
    [No Abstract]   [Full Text] [Related]  

  • 62. The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract.
    de Mulder PH; Sternberg CN; van Oosterom AT; Fossa SD
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):65-9. PubMed ID: 7512278
    [No Abstract]   [Full Text] [Related]  

  • 63. A case of urothelial carcinoma with successful continuation of enfortumab vedotin without dose reduction despite grade 3 diffuse erythema with fever.
    Yoshitani S; Kaneda K; Nishida M; Komura K; Moriwaki S; Fukunaga A
    Eur J Dermatol; 2024 Apr; 34(2):214-216. PubMed ID: 38907560
    [No Abstract]   [Full Text] [Related]  

  • 64. Enfortumab vedotin for cisplatin-ineligible urothelial cancer.
    Pignot G
    Lancet Oncol; 2021 Jun; 22(6):748-749. PubMed ID: 33991513
    [No Abstract]   [Full Text] [Related]  

  • 65. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
    Rexer H; Ohlmann CH; Gschwend J;
    Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
    [No Abstract]   [Full Text] [Related]  

  • 66. Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
    Benjamin DJ; Lythgoe MP; Rezazadeh A
    BJU Int; 2023 Jun; 131(6):691-693. PubMed ID: 36877951
    [No Abstract]   [Full Text] [Related]  

  • 67. Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma.
    Miron B; Geynisman DM
    Eur Urol; 2022 Oct; 82(4):374-376. PubMed ID: 35752503
    [No Abstract]   [Full Text] [Related]  

  • 68. Erdafitinib (Balversa) for urothelial carcinoma.
    Med Lett Drugs Ther; 2024 May; 66(1702):e83-e84. PubMed ID: 38696316
    [No Abstract]   [Full Text] [Related]  

  • 69. Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors.
    Blumenreich MS; Yagoda A; Natale RB; Watson RC
    Cancer; 1982 Aug; 50(3):435-8. PubMed ID: 7093886
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Response and Development of Immune-Related Adverse Events in an 83-Year-Old Man With Metastatic Urothelial Cancer.
    Mehra KK; Petrylak DP
    Oncology (Williston Park); 2018 Mar; 32(3):132-6. PubMed ID: 29548069
    [No Abstract]   [Full Text] [Related]  

  • 71. FDA Approves First Agent to Treat Locally Advanced, Metastatic Urothelial Cancer.
    Kahl KL
    Oncology (Williston Park); 2020 Jan; 34(1):11. PubMed ID: 32645199
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A distinctive bullous skin reaction associated with enfortumab vedotin-ejfv treatment for metastatic urothelial cancer: A case report.
    Krause T; Bonnekoh H; Dilling A; Nast A; Metz M
    J Dtsch Dermatol Ges; 2021 Dec; 19(12):1781-1783. PubMed ID: 34786831
    [No Abstract]   [Full Text] [Related]  

  • 73. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
    Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
    Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
    Hashimoto H; Tanaka Y; Murata M; Ito T
    Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
    Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Saruta M; Takahara K; Fujita K; Minami T; Adachi T; Hirasawa Y; Hashimoto T; Ohno Y; Uemura H; Shiroki R; Azuma H; Kimura T
    Int J Urol; 2024 Apr; 31(4):342-347. PubMed ID: 38113343
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.
    Hasegawa T; Oyama N; Kasamatsu H; Chino T; Taga M; Hasegawa M
    J Dermatol; 2022 Dec; 49(12):e453-e454. PubMed ID: 36052729
    [No Abstract]   [Full Text] [Related]  

  • 77. [New paradigms in the second line treatment for advanced and metastatic urothelial carcinoma.].
    Vidal N; Puente J
    Arch Esp Urol; 2020 Dec; 73(10):1007-1015. PubMed ID: 33269719
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ramucirumab plus docetaxel for urothelial carcinoma.
    Baker H
    Lancet Oncol; 2016 Apr; 17(4):e140. PubMed ID: 26973322
    [No Abstract]   [Full Text] [Related]  

  • 79. Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
    Aggen DH; Chu CE; Rosenberg JE
    Clin Cancer Res; 2023 Apr; 29(8):1377-1380. PubMed ID: 36749325
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
    Singh AM; Guevara-Patino JA; Wang X; Li R; Sonpavde G; Jain RK
    BioDrugs; 2023 Jul; 37(4):505-520. PubMed ID: 37256534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.